Management of Castration-Resistant Prostate Cancer: Envisioning a Chronic Disease Paradigm
This is a very exciting era in the management of castration-resistant prostate cancer (CRPC). The approval of several novel agents has given prostate cancer patients and their treating physicians many new and effective therapeutic options. Newly approved agents and those in the pipeline present the real possibility of prolonging survival and the hope of turning the disease into a chronic condition. Moving forward, focus will continue to be on defining the optimal use and sequencing of these agents and supporting the clinical trials needed to accomplish this task. In order for health care providers to take full advantage of these new therapies they must feel competent in their utilization.
This activity will focus on current treatment options, challenges, and considerations in treating patients with castration-resistant prostate cancer as well as optimizing patient outcomes, clinical application of new agents, sequencing strategies and potential combinations of agents.
This educational activity is designed to meet the needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.
Following this program, participants should be able to:
- Discuss prostate cancer disease progression and clinical criteria for defining CRPC
- Describe the mechanism of action of newly approved agents and those under investigation for the treatment of CRPC
- Review the most recent NCCN Guidelines and assess strategies to integrate the new and emerging therapies into cancer clinical practice for the treatment of CRPC
- Evaluate patient and disease characteristics that influence treatment choice and formulate a management plan to address specific considerations
James Mohler, MD
Associate Director and Senior-Vice President for Translational Research
Chair, Department of Urology
Professor of Oncology
Roswell Park Cancer Institute
Buffalo, New York
Leonard G. Gomella, MD, FACS
Chairman, Department of Urology
Associate Director of Clinical Affairs
Jefferson Kimmel Cancer Center
Thomas Jefferson University
- 0.75 Participation
- 0.78 Nurse
- 0.75 Pharmacist
- 0.75 Physician